Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Avastin Compounding Does Not Increase Endophthalmitis Risk, Study Says

This article was originally published in The Pink Sheet Daily

Executive Summary

Observational cohort data suggest infection risk is lower with off-label use of compounded Avastin than with Genentech's approved ophthalmic treatment, Lucentis, although not statistically significant.

You may also be interested in...



Avastin Safety Questions In Wet AMD Linger With Two-Year CATT Results

Over two years, serious adverse events occurred at a 40% rate for patients treated with Avastin and at a 32% rate for patients receiving Lucentis, CATT researchers report in an article published in the journal Ophthalmology.

Lucentis And Avastin Stack Up In CATT, Forcing Genentech/Novartis To Play Defense

The efficacy of low-cost Avastin and pricier Lucentis for the treatment of wet-AMD are similar in the first head-to-head clinical trial to compare the two drugs, though Novartis and Genentech call out safety uncertainties.

CDER, CBER Not Seeing Hiring Slowdown Despite US FDA Warnings

FDA officials have said hiring could be slowed if an inflationary pay increase is not included in the agency budget, but CDER and CBER continue to add staff at a steady pace.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS078813

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel